![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
|
|
|
|
|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Received for publication February 28, 2005.
Revised April 12, 2005.
Accepted for publication May 5, 2005.
Cyclooxygenase-3 (COX-3), a novel COX splice variant, was suggested as the key to unlocking the mystery of the mechanism of action of acetaminophen. While COX-3 might have COX activity in canine, and this activity might be inhibited by acetaminophen, its low expression level and the kinetics indicate unlikely clinical relevance. In rodents and humans COX-3 encodes proteins with completely different amino acid sequences than COX-1 or COX-2 and without COX activity, therefore it is improbable that COX-3 in these species plays a role in prostaglandin-mediated fever and pain. The aim of this review is an evaluation of the literature which seeks to point out critical theoretical and methodological limitations of the COX-3 studies which led several investigators to scientifically questionable conclusions.
Key words:
COX-3, acetaminphen, cyclooxygenase, fever, pain, prostaglandin
This article has been cited by other articles:
|
|
 |
|
  B. Hinz, O. Cheremina, and K. Brune Acetaminophen (paracetamol) is a selective cyclooxygenase-2 inhibitor in man FASEB J, February 1, 2008; 22(2): 383 - 390. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. L. Van Dyke, M. L. Cote, G. Prysak, G. B. Claeys, A. S. Wenzlaff, and A. G. Schwartz Regular Adult Aspirin Use Decreases the Risk of Non-Small Cell Lung Cancer among Women Cancer Epidemiol. Biomarkers Prev., January 1, 2008; 17(1): 148 - 157. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. C. Poulsen, P. J. Moughan, and M. C. Kruger Long-Chain Polyunsaturated Fatty Acids and the Regulation of Bone Metabolism Experimental Biology and Medicine, November 1, 2007; 232(10): 1275 - 1288. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Ishida, T. Sato, M. Irifune, K.-i. Tanaka, N. Nakamura, and T. Nishikawa Effect of acetaminophen, a cyclooxygenase inhibitor, on Morris water maze task performance in mice J Psychopharmacol, September 1, 2007; 21(7): 757 - 767. [Abstract] [PDF]
|
|
|
|
 |
|
 S. R Knowles, A. M Drucker, E. A Weber, and N. H Shear Management Options for Patients with Aspirin and Nonsteroidal Antiinflammatory Drug Sensitivity Ann. Pharmacother., July 1, 2007; 41(7): 1191 - 1200. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Tahara, H. Kusuhara, M. Chida, E. Fuse, and Y. Sugiyama Is the Monkey an Appropriate Animal Model to Examine Drug-Drug Interactions Involving Renal Clearance? Effect of Probenecid on the Renal Elimination of H2 Receptor Antagonists J. Pharmacol. Exp. Ther., March 1, 2006; 316(3): 1187 - 1194. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. L. Simmons, N. V. Chandrasekharan, D. Hu, K. L. Roos, J. Tomsik, B. Kis, J. A. Snipes, and D. W. Busija Comments on "Acetaminophen and the Cyclooxygenase-3 Puzzle: Sorting out Facts, Fictions, and Uncertainties" J. Pharmacol. Exp. Ther., December 1, 2005; 315(3): 1412 - 1414. [Full Text] [PDF]
|
|
|
|
|
|
B. Kis, J. A. Snipes, and D. W. Busija Response to Comments on "Acetaminophen and the Cyclooxygenase-3 Puzzle: Sorting out Facts, Fictions, and Uncertainties" J. Pharmacol. Exp. Ther., December 1, 2005; 315(3): 1415 - 1416. [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
